胎盘:在骨科运动医学中的应用
本文为系统综述,检索PubMed和MEDLINE,纳入29项动物研究和6项人体研究,评估胎盘来源细胞或组织同种异体移植物用于骨科运动医学适应证的安全性和疗效。结果显示结局总体积极,但胎盘组织来源、临床适应证和给药途径高度可变,无法得出确定性结论;美国尚无获批的胎盘来源生物制剂用于这些适应证。
要点
- 29项动物研究和6项人体研究显示胎盘来源治疗结局总体积极。
- 胎盘组织来源、临床适应证和给药途径在研究间高度可变。
- 美国尚无获批的胎盘来源生物制剂用于骨科运动医学适应证。
核心结论
- 综述发现胎盘细胞类型、组织制备、给药途径和治疗方案高度可变,无法得出任何确定性结论。
- 目前胎盘的临床使用仅限于商业胎盘组织同种异体移植物,美国尚无获批用于骨科运动医学适应证的胎盘来源生物制剂。
- 本综述显示胎盘细胞或组织同种异体移植物的应用似乎安全,并有可能改善骨科运动医学适应证的结局。
研究设计与样本
- 系统综述,使用共63个关键词组合检索PubMed和MEDLINE数据库。
- 纳入描述胎盘细胞和/或组织用于骨科运动医学适应证的已发表文章,收集胎盘组织类型、适应证、动物模型、研究设计、治疗方案、安全性和疗效结局信息。
- 结果按适应证分类,并按动物模型亚分类;共纳入29项动物研究和6项人体研究。
主要发现
- 29项动物研究和6项人体研究报告的胎盘来源治疗结局总体积极。
- 14项动物研究描述胎盘组织用于肌腱损伤,13项用于骨关节炎或关节软骨损伤,3项用于韧带损伤,1项用于滑膜炎。
- 动物研究使用了胎盘来源的培养扩增细胞(上皮细胞或间充质干细胞)和胎盘组织同种异体移植物。
- 所有人体研究均使用商业胎盘同种异体移植物。
- 6项人体研究中有5项研究足踝病理状况的治疗,1项研究膝骨关节炎的治疗。
临床怎么用
- 目前胎盘的临床使用仅限于商业胎盘组织同种异体移植物。
- 美国尚无获批用于骨科运动医学适应证的胎盘来源生物制剂。
局限性
- 综述指出所报告的研究数量少。
- 胎盘细胞类型、胎盘组织制备、给药途径和治疗方案高度可变,无法得出任何确定性结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Placenta has a long history of use for treating burns and wounds. It is a rich source of collagen and other extracellular matrix proteins, tissue reparative growth factors, and stem cells, including mesenchymal stem cells (MSCs). Recent data show its therapeutic potential for orthopaedic sports medicine indications. PURPOSE: To provide orthopaedic surgeons with an anatomic description of the placenta, to characterize its cellular composition, and to review the literature reporting the use of placenta-derived cells and placental tissue allografts for orthopaedic sports medicine indications in animal models and in humans. STUDY DESIGN: Systematic review. METHODS: Using a total of 63 keyword combinations, the PubMed and MEDLINE databases were searched for published articles describing the use of placental cells and/or tissue for orthopaedic sports medicine indications. Information was collected on placental tissue type, indications, animal model, study design, treatment regimen, safety, and efficacy outcomes. Results were categorized by indication and subcategorized by animal model. RESULTS: Outcomes for 29 animal studies and 6 human studies reporting the use of placenta-derived therapeutics were generally positive; however, the placental tissue source, clinical indication, and administration route were highly variable across these studies. Fourteen animal studies described the use of placental tissue for tendon injuries, 13 studies for osteoarthritis or articular cartilage injuries, 3 for ligament injuries, and 1 for synovitis. Both placenta-derived culture-expanded cells (epithelial cells or MSCs) and placental tissue allografts were used in animal studies. In all human studies, commercial placental allografts were used. Five of 6 human studies examined the treatment of foot and ankle pathological conditions, and 1 studied the treatment of knee osteoarthritis. CONCLUSION: A review of the small number of reported studies revealed a high degree of variability in placental cell types, placental tissue preparation, routes of administration, and treatment regimens, which prohibits making any definitive conclusions. Currently, the clinical use of placenta is limited to only commercial placental tissue allografts, as there are no placenta-derived biological drugs approved for the treatment of orthopaedic sports medicine conditions in the United States. However, this review shows that the application of placental cells or tissue allografts appears to be safe and has potential to improve outcomes for orthopaedic sports medicine indications.
引用
- McIntyre JA, Jones IA, Danilkovich A, et al. The Placenta: Applications in Orthopaedic Sports Medicine. Am J Sports Med. 2017. PMID: 28375638. doi:10.1177/0363546517697682
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。